Highlights of US CDER drug safety activity in 2003

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2004年 / 1005卷 / 1期

关键词：

Public Health; Medication Error; Product Testing; Drug Evaluation; Prescription Medicine;

D O I：

10.2165/00128415-200410050-00005

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[21] A Review of CDER's Novel Drug Approvals for 2016
John Jenkins
Journal of Chinese Pharmaceutical Sciences, 2017, (02) : 161 - 162
[22] Drug Safety scientometrics overview highlights public health issues
Gorry, Philippe
Seoane-Vazquez, Enrique
17TH INTERNATIONAL CONFERENCE ON SCIENTOMETRICS & INFORMETRICS (ISSI2019), VOL II, 2019, : 2754 - 2755
[23] JPI interviews Moheb Nasr, PhD: Director, Office of New Drug Quality Assesment (ONDQA), CDER, US FDA
不详
Journal of Pharmaceutical Innovation, 2007, 2 (3-4) : 67 - 70
[24] DRUG SAFETY US, EU drug inspectors team up
Erickson, Britt
CHEMICAL & ENGINEERING NEWS, 2017, 95 (44) : 17 - 17
[25] The unfinished business of US drug safety regulation
Evans, BJ
Flockhart, DA
FOOD AND DRUG LAW JOURNAL, 2006, 61 (01) : 45 - 63
[26] Update on the Office of Drug Safety at the US FDA
Reactions Weekly, 2004, 1015 (1) : 3 - 4
[27] Safety Highlights
Washington, Jack B.
Yan, Chunhui
Wilkinson, Peter
Reid, Marc
ACS CHEMICAL HEALTH & SAFETY, 2020, 27 (03) : 148 - 149
[28] US doctors debate safety of abortifacient drug
Tanne, JH
BRITISH MEDICAL JOURNAL, 2006, 332 (7533): : 71 - 71
[29] Stronger drug quality and safety laws in the US
Reactions Weekly, 2013, 1482 (1) : 5 - 5
[30] Safety Highlights
Reid, Marc
Perlmutter, Sarah J.
Williams, Benjamin
ACS CHEMICAL HEALTH & SAFETY, 2020, 27 (01) : 71 - 72

← 1 2 3 4 5 →